Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). Background: Enoblituzumab, an Fc optimized humanized IgG1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results